原谅我开始放纵了的个人主页 - 老虎社区

原谅我开始放纵了

原谅我开始放纵了

不做价值投资，不做时间的朋友，投资的本质就是投机

IP属地：上海

107关注

954粉丝

1主题

0勋章

原谅我开始放纵了

2021-07-16

$Creatd Inc(CRTD)$飞吧，小短腿，挂4.5出

原谅我开始放纵了

2021-07-16

$Moving iMage Technologies Inc.(MITQ)$留下了没有格局的眼泪

原谅我开始放纵了

2021-07-14

最近在$ContextLogic Inc.(WISH)$里面套着，贪心了冲高没走，$箩筐技术(LKCO)$等低点接着补

原谅我开始放纵了

2021-07-06

$微博(WB)$这股牛逼啊，这都能涨[捂脸]

原谅我开始放纵了

2021-06-25

$ContextLogic Inc.(WISH)$虽然没到16，但是这不重要，重要是要起飞了

原谅我开始放纵了

2021-06-25

$ContextLogic Inc.(WISH)$一觉醒来果然拉了，还不止13.5，做空的还好么

原谅我开始放纵了

2021-06-24

$ContextLogic Inc.(WISH)$洗洗睡吧，睁眼还是13.5

原谅我开始放纵了

2021-06-24

$ContextLogic Inc.(WISH)$低开下杀然后16见

原谅我开始放纵了

2021-06-22

$AMC院线(AMC)$指望002？007来了都救不了

原谅我开始放纵了

2021-06-22

$AMC院线(AMC)$这股情绪过了就那样了，买$ContextLogic Inc.(WISH)$不好么，短期、长持都很好

原谅我开始放纵了

2021-06-21

$阿什福德酒店管理信托公司(AHT)$为啥跌

原谅我开始放纵了

2021-06-18

11继续加仓买多$ContextLogic Inc.(WISH)$60建仓继续空$AMC院线(AMC)$

原谅我开始放纵了

2021-06-10

$极光(JG)$哈哈哈垃圾只能去垃圾桶了，等了这么久，就这…

原谅我开始放纵了

2021-06-10

$极光(JG)$这是亏损同比下降了是么，利好？tm等了这么久就这…

原谅我开始放纵了

2021-06-09

看到你我就不慌了，14

@13幺:$ContextLogic Inc.(WISH)$Must have patience.

原谅我开始放纵了

2021-06-09

$ContextLogic Inc.(WISH)$请叫我韭菜，第一次追高就追山顶

原谅我开始放纵了

2021-06-09

$ContextLogic Inc.(WISH)$神秘力量果然牛逼

原谅我开始放纵了

2021-06-06

谁总结下，大利好？

TNXP: Interim Analysis for Phase 3 RALLY Trial in 3Q21; Topline Results in 1Q22…

原谅我开始放纵了

2021-06-03

$途牛(TOUR)$来吧，小板凳已经搬好了

原谅我开始放纵了

2021-05-28

中报期，是不是可以各种炒财报了

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3573714277045690,"uuid":"3573714277045690","gmtCreate":1610620253976,"gmtModify":1617947814627,"name":"原谅我开始放纵了","pinyin":"ylwksfzlyuanliangwokaishifangzongle","introduction":"","introductionEn":"","signature":"不做价值投资，不做时间的朋友，投资的本质就是投机","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":954,"headSize":107,"tweetSize":110,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":4,"name":"文化虎","nameTw":"文化虎","represent":"学有所成","factor":"发布30条非转发主帖,其中3条优质帖","iconColor":"8867FB","bgColor":"BDC5FF"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e2c640e5de444f3b84fa7170b007e676-1-SNDL","templateUuid":"e2c640e5de444f3b84fa7170b007e676","name":"“SNDL”人气虎","description":"一周内发布的“SNDL”相关帖子优质程度排名前3","bigImgUrl":"https://static.tigerbbs.com/2ba70f50467799d43bcf1b3972785ba7","smallImgUrl":"https://static.tigerbbs.com/5ecd4bad5ec93214c9325a5452cdd1b5","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":"SNDL","stampPosition":0,"hasStamp":1,"allocationCount":3,"allocatedDate":"2021.12.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2002},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"上海","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":170503975,"gmtCreate":1626440144997,"gmtModify":1626440144997,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CRTD\">$Creatd Inc(CRTD)$</a>飞吧，小短腿，挂4.5出","listText":"<a href=\"https://laohu8.com/S/CRTD\">$Creatd Inc(CRTD)$</a>飞吧，小短腿，挂4.5出","text":"$Creatd Inc(CRTD)$飞吧，小短腿，挂4.5出","images":[{"img":"https://static.tigerbbs.com/49381a26371d178e27efff92d6dbe391","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170503975","isVote":1,"tweetType":1,"viewCount":1886,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":147404334,"gmtCreate":1626370969928,"gmtModify":1626370969928,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MITQ\">$Moving iMage Technologies Inc.(MITQ)$</a>留下了没有格局的眼泪","listText":"<a href=\"https://laohu8.com/S/MITQ\">$Moving iMage Technologies Inc.(MITQ)$</a>留下了没有格局的眼泪","text":"$Moving iMage Technologies Inc.(MITQ)$留下了没有格局的眼泪","images":[{"img":"https://static.tigerbbs.com/40738894fc768cc78e1441de4de765ba","width":"1242","height":"2208"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/147404334","isVote":1,"tweetType":1,"viewCount":2537,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":144399049,"gmtCreate":1626266158681,"gmtModify":1626266158681,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"最近在<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>里面套着，贪心了冲高没走，<a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$</a>等低点接着补","listText":"最近在<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>里面套着，贪心了冲高没走，<a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$</a>等低点接着补","text":"最近在$ContextLogic Inc.(WISH)$里面套着，贪心了冲高没走，$箩筐技术(LKCO)$等低点接着补","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/144399049","isVote":1,"tweetType":1,"viewCount":2872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":157642836,"gmtCreate":1625581565525,"gmtModify":1625581565525,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WB\">$微博(WB)$</a>这股牛逼啊，这都能涨[捂脸]&nbsp;","listText":"<a href=\"https://laohu8.com/S/WB\">$微博(WB)$</a>这股牛逼啊，这都能涨[捂脸]&nbsp;","text":"$微博(WB)$这股牛逼啊，这都能涨[捂脸]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/157642836","isVote":1,"tweetType":1,"viewCount":3011,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3583538139427485","authorId":"3583538139427485","name":"大麻其实就是韭菜","avatar":"https://static.tigerbbs.com/5848612ad3ecbb97bdf0d76f20753545","crmLevel":2,"crmLevelSwitch":0},"content":"估计是之前70 80进场的把股价拖住了","text":"估计是之前70 80进场的把股价拖住了","html":"估计是之前70 80进场的把股价拖住了"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":126593116,"gmtCreate":1624577930635,"gmtModify":1624577930635,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>虽然没到16，但是这不重要，重要是要起飞了","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>虽然没到16，但是这不重要，重要是要起飞了","text":"$ContextLogic Inc.(WISH)$虽然没到16，但是这不重要，重要是要起飞了","images":[{"img":"https://static.tigerbbs.com/d45033dcaf03be27a11c9bc9ffcbf0a4","width":"1242","height":"670"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126593116","isVote":1,"tweetType":1,"viewCount":2227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":126664407,"gmtCreate":1624564254609,"gmtModify":1624564254609,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>一觉醒来果然拉了，还不止13.5，做空的还好么","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>一觉醒来果然拉了，还不止13.5，做空的还好么","text":"$ContextLogic Inc.(WISH)$一觉醒来果然拉了，还不止13.5，做空的还好么","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126664407","isVote":1,"tweetType":1,"viewCount":2815,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":126352495,"gmtCreate":1624545503617,"gmtModify":1624545503617,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>洗洗睡吧，睁眼还是13.5","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>洗洗睡吧，睁眼还是13.5","text":"$ContextLogic Inc.(WISH)$洗洗睡吧，睁眼还是13.5","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126352495","isVote":1,"tweetType":1,"viewCount":1684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":128755427,"gmtCreate":1624533710769,"gmtModify":1624533710769,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>低开下杀然后16见","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>低开下杀然后16见","text":"$ContextLogic Inc.(WISH)$低开下杀然后16见","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/128755427","isVote":1,"tweetType":1,"viewCount":2946,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":120836980,"gmtCreate":1624318398040,"gmtModify":1624318398040,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>指望002？007来了都救不了","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>指望002？007来了都救不了","text":"$AMC院线(AMC)$指望002？007来了都救不了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/120836980","isVote":1,"tweetType":1,"viewCount":2783,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":120159357,"gmtCreate":1624316527679,"gmtModify":1624316527679,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>这股情绪过了就那样了，买<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>不好么，短期、长持都很好","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>这股情绪过了就那样了，买<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>不好么，短期、长持都很好","text":"$AMC院线(AMC)$这股情绪过了就那样了，买$ContextLogic Inc.(WISH)$不好么，短期、长持都很好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/120159357","isVote":1,"tweetType":1,"viewCount":3803,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":167671716,"gmtCreate":1624267758335,"gmtModify":1624267758335,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AHT\">$阿什福德酒店管理信托公司(AHT)$</a>为啥跌","listText":"<a href=\"https://laohu8.com/S/AHT\">$阿什福德酒店管理信托公司(AHT)$</a>为啥跌","text":"$阿什福德酒店管理信托公司(AHT)$为啥跌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/167671716","isVote":1,"tweetType":1,"viewCount":2115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168228989,"gmtCreate":1623976808741,"gmtModify":1623976808741,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"11继续加仓买多<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>60建仓继续空<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>","listText":"11继续加仓买多<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>60建仓继续空<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>","text":"11继续加仓买多$ContextLogic Inc.(WISH)$60建仓继续空$AMC院线(AMC)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168228989","isVote":1,"tweetType":1,"viewCount":1344,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":183220617,"gmtCreate":1623333305039,"gmtModify":1623333305039,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a>哈哈哈垃圾只能去垃圾桶了，等了这么久，就这…","listText":"<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a>哈哈哈垃圾只能去垃圾桶了，等了这么久，就这…","text":"$极光(JG)$哈哈哈垃圾只能去垃圾桶了，等了这么久，就这…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/183220617","isVote":1,"tweetType":1,"viewCount":1896,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574201674789492","authorId":"3574201674789492","name":"flyone","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0},"content":"这个股不用考虑了","text":"这个股不用考虑了","html":"这个股不用考虑了"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":183118046,"gmtCreate":1623314082985,"gmtModify":1623314082985,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a>这是亏损同比下降了是么，利好？tm等了这么久就这…","listText":"<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a>这是亏损同比下降了是么，利好？tm等了这么久就这…","text":"$极光(JG)$这是亏损同比下降了是么，利好？tm等了这么久就这…","images":[{"img":"https://static.tigerbbs.com/4cea36378faf47df19c90becdd479808","width":"1242","height":"756"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/183118046","isVote":1,"tweetType":1,"viewCount":2010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":189173258,"gmtCreate":1623249580274,"gmtModify":1623249580274,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"看到你我就不慌了，14","listText":"看到你我就不慌了，14","text":"看到你我就不慌了，14","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/189173258","repostId":"189148737","repostType":1,"repost":{"id":189148737,"gmtCreate":1623249333529,"gmtModify":1634035349768,"author":{"id":"3568607492959902","authorId":"3568607492959902","name":"13幺","avatar":"https://static.tigerbbs.com/8c3c8f004f85f093f044d75ebe3bdf36","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>Must have patience.","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>Must have patience.","text":"$ContextLogic Inc.(WISH)$Must have patience.","images":[{"img":"https://static.tigerbbs.com/0c2bd635d3225da9c068a78780534d08","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/189148737","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":189120082,"gmtCreate":1623248514146,"gmtModify":1623249810262,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>请叫我韭菜，第一次追高就追山顶","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>请叫我韭菜，第一次追高就追山顶","text":"$ContextLogic Inc.(WISH)$请叫我韭菜，第一次追高就追山顶","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":7,"commentSize":14,"repostSize":0,"link":"https://laohu8.com/post/189120082","isVote":1,"tweetType":1,"viewCount":2833,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575764178135145","authorId":"3575764178135145","name":"MaRo","avatar":"https://static.tigerbbs.com/8c7022bbcac13197c84f0d963050133e","crmLevel":4,"crmLevelSwitch":0},"content":"多少入的？","text":"多少入的？","html":"多少入的？"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":189900059,"gmtCreate":1623236953571,"gmtModify":1623236953571,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>神秘力量果然牛逼","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>神秘力量果然牛逼","text":"$ContextLogic Inc.(WISH)$神秘力量果然牛逼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/189900059","isVote":1,"tweetType":1,"viewCount":2591,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581923941113534","authorId":"3581923941113534","name":"3c73c40d","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0},"content":"神秘力量是什么","text":"神秘力量是什么","html":"神秘力量是什么"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":115856665,"gmtCreate":1622976410457,"gmtModify":1622976410457,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"谁总结下，大利好？","listText":"谁总结下，大利好？","text":"谁总结下，大利好？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/115856665","repostId":"2140440456","repostType":2,"repost":{"id":"2140440456","pubTimestamp":1622807220,"share":"https://www.laohu8.com/m/news/2140440456?lang=&edition=full","pubTime":"2021-06-04 19:47","market":"us","language":"en","title":"TNXP: Interim Analysis for Phase 3 RALLY Trial in 3Q21; Topline Results in 1Q22…","url":"https://stock-news.laohu8.com/highlight/detail?id=2140440456","media":"Zacks Small Cap Research","summary":"By David Bautz, PhD\n NASDAQ:TNXP\nREAD THE FULL TNXP RESEARCH REPORT\nBusiness Update\nTonix Pharmaceut","content":"<html><body><p>By David Bautz, PhD</p>\n<p> NASDAQ:TNXP</p>\n<p>READ THE FULL TNXP RESEARCH REPORT</p>\n<p><span><strong>Business Update</strong></span></p>\n<p>Tonix Pharmaceutical Holdings Corp. (NASDAQ:TNXP) has undergone a transformation over the past year as it has built up a robust pipeline of clinical stage assets focused on the treatment of central nervous system (CNS) and immunological diseases. In addition, the company’s balance sheet has never been stronger. As of March 31, 2021, Tonix had approximately $164.2 million in cash and cash equivalents along with no debt, no preferred shares, and a very limited number of warrants. Investors can look for the following milestones to occur over the next 6-12 months (all trials in U.S. unless otherwise noted):</p>\n<p><span>TNX-102 SL:       Phase 3 RALLY Trial in Fibromyalgia: Interim Analysis – 3Q21</span></p>\n<p>                             Phase 3 RALLY Trial in Fibromyalgia: Topline Data – 1Q22</p>\n<p>                             Phase 3 trial in PTSD (in Kenya): Initiation – 3Q21</p>\n<p>TNX-1300:          Phase 2 trial in Cocaine Intoxication: Initiation – 3Q21</p>\n<p>TNX-1900:          Phase 2 trial in Chronic Migraine: Initiation – 3Q21</p>\n<p>TNX-601 CR:      Phase 2 trial in Major Depressive Disorder: Initiation – 4Q21</p>\n<p>TNX-2100:          Skin Test for COVID-19: Initiation – 4Q21</p>\n<p>TNX-1800:          Phase 1 trial for COVID-19 Vaccine: Initiation – 1H22</p>\n<p><em>Interim Analysis for RALLY Trial in 3Q21; Topline Results in 1Q22</em></p>\n<p>Tonix is currently conducting the Phase 3 RALLY trial, a double blind, randomized, placebo controlled trial designed to evaluate the safety and efficacy of TNX-102 SL in patients with fibromyalgia (FM) (NCT04508621). It is similar in design to the Phase 3 RELIEF trial, which the company announced positive results for in December 2020, but with an additional 200 patients. The RELIEF trial showed that the 5.6 mg dose of TNX-102 SL achieved statistically significant pain reduction over placebo at Week 14 (<em>P</em>=0.01). For an overview of those results, see our report here. </p>\n<p>In March 2021, Tonix announced that 50 percent of the planned total number of participants had been randomized in the RALLY trial and an interim analysis will take place after the 14-week treatment period has been completed. There are four potential outcomes from the interim analysis:</p>\n<p>1)   Stop the study early for success</p>\n<p>2)   Continue to enroll the study as planned</p>\n<p>3)   Continue to enroll the study but increase the total number of participants</p>\n<p>4)   Stop the study for futility</p>\n<p>We estimate the result of the interim analysis will be available in the third quarter of 2021 and topline results for the full trial will be available in the first quarter of 2022. Positive results for the RALLY trial would put Tonix in a position to potentially file an NDA in 2022. </p>\n<p>Treating FM represents a substantial potential market opportunity. There are currently three FDA approved FM treatments; Lyrica®, Cymbalta®, and Savella®. Peak sales for both Lyrica and Cymbalta were $5 billion each for all indications (estimated approximately $1 billion each for FM), while Savella had peak sales in FM of approximately $100 million (EvaluatePharma). Lyrica and Cymbalta are both off patent, and Savella will lose patent protection in January 2023, however with each of those therapies having undesirable side effects and a lack of efficacy for a number of patients (50% of FM patients switch or discontinue therapy after 12 months), an effective therapy with a tolerable side effect profile is likely to take significant market share.</p>\n<p><em>TNX-1300 Update</em></p>\n<p>We anticipate Tonix initiating a Phase 2 clinical trial of TNX-1300, a double mutant cocaine esterase, for the treatment of cocaine intoxication before the end of the third quarter of 2021. Tonix licensed the asset in May 2019 from Columbia University, which has breakthrough therapy designation from the U.S. FDA. </p>\n<p>TNX-1300 is a recombinant enzyme derived from the <em>cocE</em> gene of a <em>Rhodococcus</em> species that utilizes cocaine as a sole source of carbon and nitrogen (Bresler <em>et al.</em>, 2000). The degradation of cocaine by the enzyme is shown in the following figure.</p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/k8j.6TnbeNE_KoiJ1CdWnQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/scr.zacks.com/e50aa2fb8441cf5d6e551c308eff80c4\"/></p>\n<p>The CocE enzyme was tested in a rat model of cocaine toxicity to determine if it could protect the animals from cocaine-induced lethality (Cooper <em>et al</em>., 2006). The following chart shows that administration of increasing concentrations of CocE (CE) 1 minute before a lethal 180 mg/kg IP dose of cocaine results in increasing protection from cocaine-induced lethality (shown as “percent affected”). In fact, it required a 1000 mg/kg dose of cocaine to overcome the protective effects of 1 mg CocE (LD<sub>50</sub> for IP dose is 70 mg/kg cocaine). BChe (butyrylcholinesterase) is an endogenous human esterase that also degrades cocaine into benzoic acid and ecgonine methyl ester, however its catalytic efficiency is much lower than CocE (Xie <em>et al</em>., 1999), and as shown in the following figure it is not nearly as efficient at protecting animals from a lethal dose of cocaine.</p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/OZ.DMiLjBzoJ5bLPm0JTbw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/scr.zacks.com/3fd98e984bde9b23e5a4b4d1e5617d93\"/></p>\n<p>One of the issues with the native CocE enzyme is that its half-life is only a few minutes at physiological temperature (37ºC) (Cooper<em> et al</em>., 2006). Thus, a study was performed to develop thermostable variants of CocE using a computational approach along with<em> in vitro</em> and <em>in vivo </em>studies (Gao <em>et al</em>., 2009). A variant was identified with two amino acid substitutions (T172R/G173Q) that resulted in increased stability at 37ºC. The following figure shows that the double mutant CocE enzyme retains more of its activity at 37ºC for a longer period of time compared to the wild-type enzyme or the enzymes with <a href=\"https://laohu8.com/S/AONE\">one</a> or the other mutations. </p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/4jxL8Azw1L4k0tFpvx1etQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/scr.zacks.com/419c9663f65a1ba009ac7e1c53a35e8c\"/></p>\n<p>The double mutant CocE enzyme (then called RBP-8000, now TNX-1300) was evaluated in a Phase 2 clinical trial conducted by Reckitt Benckiser Pharmaceuticals, the previous licensee to the product (NCT01846481). It was a double blind, placebo controlled, randomized, four-sequence, two-period cross-over study. Subjects were non-treatment seekers with a DSM-IV diagnosis of cocaine abuse. During the study period, subjects were given an IV infusion of 50 mg of cocaine over 10 minutes followed by TNX-1300 (100 mg or 200 mg) or matching placebo <a href=\"https://laohu8.com/S/AONE.U\">one</a> minute after completion of the cocaine infusion. Outcomes included pharmacokinetics of both cocaine and TNX-1300 along with any effect by TNX-1300 on cocaine-induced physiological changes (Nasser <em>et al</em>., 2014).</p>\n<p>A total of 29 subjects were randomized in the trial. Safety results showed that no anti-TNX-1300 antibodies were detected in any of the subjects at any time point. In addition, there were no clinically significant abnormalities in vital signs, clinical laboratory markers, or physical examinations. A total of seven subjects reported treatment-emergent adverse events that were considered related to treatment with any study drug, with most being assessed as mild in severity. Of note, vital signs of subjects treated with TNX-1300 returned to or below baseline earlier than subjects that received placebo, as shown in the following figure. </p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/VCfWH7qmImIXnJgLEQCG4g--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/scr.zacks.com/b1142340e00b4a9a7408a6747c15f308\"/></p>\n<p>Plasma cocaine rapidly decreased following administration of TNX-1300, with a 90% drop of peak plasma cocaine concentrations within two minutes and a 95% decline in plasma cocaine exposure. The 200 mg dose of TNX-1300 produced a longer-lasting effect on cocaine pharmacokinetics compared to the 100 mg dose. These preliminary results fully support the continued develop of TNX-1300 as a treatment for cocaine intoxication.</p>\n<p><em>TNX-1900 Update</em></p>\n<p>Tonix licensed TNX-1900, a proprietary, patented enhanced formulation of intranasally administered oxytocin for the treatment of chronic migraine and craniofacial pain, in June 2020. We anticipate the company initiating a Phase 2 clinical trial for the prophylactic treatment of chronic migraine in the third quarter of 2021. </p>\n<p>A migraine is a headache that can cause severe pain, can last up to 72 hours, has a pulsing quality, and may be associated with nausea, vomiting, phonophobia, or photophobia. Approximately one billion individuals in the world suffer from migraine headaches (GBD 2016 Headache Collaborators). In the U.S., migraines affect approximately 72 million individuals (Gooch <em>et al</em>., 2017). Chronic migraines, which are defined as having a headache at least 15 times a month for three months, are less common (1-5% of migraine sufferers). While not a fatal condition, migraines still contribute to a significant decrease in quality of life and the total estimated cost of all migraine headaches is approximately $78 billion per year (Gooch <em>et al.</em>, 2017). </p>\n<p>Migraine treatments are classified as abortive (intended to stop a migraine once it begins) or prophylactic (decrease the frequency and/or severity of migraines). Abortive treatments include triptans and ditans (which specifically target serotonin receptors), over the counter medications (that typically include some combination of a nonsteroidal anti-inflammatory drug (NSAID), acetaminophen, and/or caffeine), ergots, and small molecule calcitonin gene-related peptide (CGRP) antagonists. </p>\n<p>Antibodies that target the interaction of CGRP with its receptor represent the newest class of prophylactic treatments and include Aimovig (erenumab), which targets the CGRP receptor, and Ajovy (fremanezumab), Emgality (galcanezumab), and Vyepti (eptinezumab), which each target CGRP itself. These drugs generated approximately $1 billion in sales in 2020, and are estimated to generate 2026 sales of $4 billion (EvaluatePharma). A summary of their results in Phase 3 clinical trials is shown in the following table.</p>\n<p><img src=\"https://s.yimg.com/uu/api/res/1.2/9ef2qEYopHbQUWcahrEgXQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/scr.zacks.com/c4a816efc2f9b01837b067fe87ee85ef\"/></p>\n<p>Each of the CGRP-directed antibody treatments are administered as subcutaneous injections or infusions on a monthly or once every three months schedule. Side effects associated with CGRP antibodies are generally mild or moderate, with redness and/or pain at injection site the most common, although due to a number of core systems that CGRP is involved in there are a number of theoretical long-term adverse effects that may arise once the data (≥10 years) is available, including CGRP’s role in hypertension, wound healing, and insulin levels (Robbins, 2020).</p>\n<p><span>Oxytocin in Migraine</span></p>\n<p>While the exact cause of migraines remains to be elucidated, it appears to be associated with the hypothalamus and its communication with the spinal trigeminal nuclei and sensory trigeminovascular system, thus neuromodulators that target the trigeminal pathway could prove effective in migraines.</p>\n<p>Oxytocin is a nine amino acid peptide hormone that is involved in a wide array of biological processes, including learning and memory, anxiety, addiction, feeding behavior, maternal behavior, and processing of social information (Cilz <em>et al</em>., 2019). A review of the available literature showed that in 29/33 animal studies oxytocin increased “pain” tolerance (Rash <em>et al.</em>, 2014), which suggests it may act as an analgesic. Circumstantial evidence shows that oxytocin may be an effective migraine treatment based on the fact that increased oxytocin levels in pregnancy and during breastfeeding correlates with decreased migraine occurrence (Hoshiyama <em>et al</em>., 2012) and women who suffer from migraines report that sex (which results in a surge in oxytocin levels) provides at least temporary relief from the condition (Evans<em> et al</em>., 2001). </p>\n<p>While the potential for oxytocin as a treatment for migraine headaches appears promising, getting oxytocin to the trigeminal system is challenging due to the fact that: 1) oxytocin is a small peptide that is broken down almost immediately in the gastrointestinal system; and 2) its half-life in the blood stream is very short (3-5 min) with only limited ability to cross the blood-brain barrier, thus eliminating the availability of oral or parenteral administration. But delivered intranasally, oxytocin permeates the nasal mucosa and is transported along the trigeminal nerve pathway to the trigeminal ganglion where it can inhibit release along trigeminal neurons that synapse within the lining of the dura mater and inhibit CGRP release. Additionally, the most direct way to bypass the blood brain barrier and gain access to the CNS could be nasal administration along olfactory and trigeminal pathways to the brain (Dhuria <em>et al</em>., 2010).</p>\n<p>Multiple preclinical studies have examined the potential for oxytocin as a migraine treatment. Oxytocin receptors are present in rat trigeminal neurons, and the vast majority of neurons that express oxytocin receptors also express CGRP (Tzabazis <em>et al.</em>, 2016). Intranasal administration of radiolabeled oxytocin in rats results in a very high concentration of oxytocin in all three branches of the trigeminal nerve and trigeminal ganglion (Tzabazis <em>et al</em>., 2017). Administration of nitroglycerin triggers migraine headaches in patients (Sances <em>et al</em>., 2004), thus intraperitoneal injection of nitroglycerin is utilized in a rat model of migraine (Ma <em>et al</em>., 2008). This model results in expression of <em>C-fos</em> in multiple trigeminal neurons (a marker for trigeminal nerve activation), however pre-treatment with intranasal oxytocin markedly reduces the expression of <em>C-fos</em>, thus pointing to a potential role of oxytocin in preventing pain transmission. </p>\n<p>A Phase 2 clinical trial of intranasal oxytocin was previously conducted by Trigemina, Inc., from which Tonix acquired TNX-1900 in June 2020. This was a double blind, placebo controlled trial in 218 mostly female migraine sufferers (143 on oxytocin; 75 on placebo) and was conducted in Chile, Australia, and New Zealand (NCT01839149). The trial consisted of a 28-day “run-in” period to establish a baseline of migraine days followed by 56 days of “as needed” dosing with either intranasal oxytocin or placebo. Results showed that while intranasal oxytocin was well tolerated, the study did not meet the primary endpoint of a reduction in migraine headache days from baseline. This was mostly due to an extremely high placebo response rate at the clinical sites in Chile, which was 74%, while subjects from New Zealand and Australia experienced a normal placebo response and showed a statistically significant difference between active and placebo groups (Tzabazis <em>et al</em>., 2017). </p>\n<p>Based on results of preclinical studies demonstrating enhanced analgesic activity of oxytocin mediated by the oxytocin receptor in the presence of magnesium, Trigemina developed a proprietary, potentiated formulation of oxytocin containing magnesium. Tonix acquired the intellectual property for this formulation and plans to advance it first in the study of chronic migraine. </p>\n<p>To follow up on the results of the prior Phase 2 trial, we anticipate Tonix conducting a classic preventative migraine Phase 2 trial of TNX-1900, which is the potentiated formulation of intranasal oxytocin, for the prophylactic treatment of chronic migraine. We expect the trial to be similarly designed to the previous Phase 2 trial with a 28-day baseline period followed by 84 days of dosing. </p>\n<p>The market opportunity in treating chronic migraine is large. We estimate approximately two million Americans suffer from chronic migraine and even taking a single digit percentage of this population could result in peak revenue of approximately $500 million. </p>\n<p><em>Licenses Anti-Viral Compound as Potential COVID-19 Treatment</em></p>\n<p>In April 2021, Tonix announced an exclusive worldwide license agreement with OyaGen, Inc. for an antiviral compound, TNX-3500 (sangivamycin, formerly OYA1), for the treatment of COVID-19 and possibly other viral diseases. Sangivamycin is a natural product that was originally isolated from <em>Streptomyces rimosus</em> and studied in the 1960’s by the National Cancer Institute (NCI) as a potential cancer therapeutic. Due to lack of efficacy the drug did not advance as an anti-cancer therapy but it did show good safety and tolerability in those trials. </p>\n<p>A recent study identified sangivamycin as an inhibitor of Ebola virus replication, and surprisingly it also inhibited the replication of Marburg virus, Lassa virus, cowpox virus, and vaccinia virus (Bennett <em>et al</em>., 2020). OyaGen followed up these results with a collaborative research project with the National Institutes of Allergy and Infectious Diseases <a href=\"https://laohu8.com/S/IRI.AU\">Integrated Research</a> Facility (NIAID-IRF) to study the effect of sangivamycin on the replication of SARS-CoV-2. Unpublished results show that the compound has strong dose-dependent antiviral activity against SARS-CoV-2 and was approximately 65 times more potent than remdesivir (Veklury®). In addition, combination treatment with sangivamycin and remdesivir show additive activity against SARS-CoV-2. </p>\n<p>Tonix will be conducting further preclinical studies to test the safety and efficacy of sangivamycin as a treatment for COVID-19 and we anticipate an update on this program later this year.</p>\n<p><span><strong>Financial Update</strong></span></p>\n<p>On May 10, 2021, Tonix announced financial results for the first quarter of 2021. As expected, the company did not report any revenues for the first quarter of 2021. Net loss available to common shareholders for the first quarter of 2021 was $20.7 million, or $0.07 per share, compared to a net loss available to common shareholders of $9.0 million, or $0.37 per share, for the first quarter of 2020. The weighted average common shares outstanding for the first quarter of 2021 were approximately 290.1 million compared to approximately 24.0 million in the first quarter of 2020.</p>\n<p>R&amp;D expenses for the first quarter of 2021 were $15.3 million, compared to $4.7 million for the first quarter of 2020. The increase was primarily due to the timing of milestones related to the Phase 3 RELIEF trial along with preparative activities for the initiation of Phase 2 trials of TNX-1300, TNX-1900, and TNX-601 CR. G&amp;A expenses for the first quarter of 2021 were $5.4 million, compared to $2.6 million for the first quarter of 2020. The increase was primarily due to increased reporting expenses, patent prosecution and maintenance costs, and an increase in salaries. </p>\n<p>As of March 31, 2021, Tonix had approximately $164.2 million in cash and cash equivalents. This was due in part to the company raising approximately $110 million from previously announced securities purchase agreements during the first quarter of 2021. As of May 7, 2021, Tonix had approximately 326.5 million common shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of approximately 350.1 million. </p>\n<p><span><strong>Conclusion</strong></span></p>\n<p>Tonix is in a very strong financial position with $164.2 million in cash and cash equivalents, which will help the company advance the multiple pipeline candidates into and through the clinic. The most immediate inflection point will be the interim analysis for the RALLY trial, which we anticipate in the third quarter of 2021. Topline results for that trial should be announced in the first quarter of 2022, and if positive will allow for the company to file an NDA likely in 2022. In addition, the company will be initiating another Phase 3 trial for TNX-102 SL in PTSD in police in Kenya in the third quarter of 2021 and potentially three Phase 2 trials for TNX-1300, TNX-1900, and TNX-601 CR before the end of 2021. Since it will be entering the clinic in the third quarter of 2021, we have incorporated TNX-1900 into our model, which has increased our valuation to $4.50 per share. </p>\n<p><strong><b>SUBSCRIBE TO ZACKS SMALL CAP RESEARCH</b></strong><strong><span><span><b><i> to receive our articles and reports emailed directly to you each morning. Please visit our </i></b><b><i>website</i></b></span><b><i><span> for additional information on Zacks SCR. </span></i></b></span></strong></p>\n<strong> </strong>\n<p><strong></strong><strong><span><span><i>DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.</i></span></span></strong></p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TNXP: Interim Analysis for Phase 3 RALLY Trial in 3Q21; Topline Results in 1Q22…</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTNXP: Interim Analysis for Phase 3 RALLY Trial in 3Q21; Topline Results in 1Q22…\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-04 19:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tnxp-interim-analysis-phase-3-114700284.html><strong>Zacks Small Cap Research</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By David Bautz, PhD\n NASDAQ:TNXP\nREAD THE FULL TNXP RESEARCH REPORT\nBusiness Update\nTonix Pharmaceutical Holdings Corp. (NASDAQ:TNXP) has undergone a transformation over the past year as it has built ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tnxp-interim-analysis-phase-3-114700284.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/mrATwC_Z.THEKyO9QbmjaQ--~B/aD0xMjU7dz00MTg7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/OzrY8JF69gHdNLjE8ABI6w--~B/aD0xMjU7dz00MTg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/e50aa2fb8441cf5d6e551c308eff80c4","relate_stocks":{"00075":"渝太地产","TNXP":"Tonix Pharmaceuticals Holding Co"},"source_url":"https://finance.yahoo.com/news/tnxp-interim-analysis-phase-3-114700284.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2140440456","content_text":"By David Bautz, PhD\n NASDAQ:TNXP\nREAD THE FULL TNXP RESEARCH REPORT\nBusiness Update\nTonix Pharmaceutical Holdings Corp. (NASDAQ:TNXP) has undergone a transformation over the past year as it has built up a robust pipeline of clinical stage assets focused on the treatment of central nervous system (CNS) and immunological diseases. In addition, the company’s balance sheet has never been stronger. As of March 31, 2021, Tonix had approximately $164.2 million in cash and cash equivalents along with no debt, no preferred shares, and a very limited number of warrants. Investors can look for the following milestones to occur over the next 6-12 months (all trials in U.S. unless otherwise noted):\nTNX-102 SL:       Phase 3 RALLY Trial in Fibromyalgia: Interim Analysis – 3Q21\n                             Phase 3 RALLY Trial in Fibromyalgia: Topline Data – 1Q22\n                             Phase 3 trial in PTSD (in Kenya): Initiation – 3Q21\nTNX-1300:          Phase 2 trial in Cocaine Intoxication: Initiation – 3Q21\nTNX-1900:          Phase 2 trial in Chronic Migraine: Initiation – 3Q21\nTNX-601 CR:      Phase 2 trial in Major Depressive Disorder: Initiation – 4Q21\nTNX-2100:          Skin Test for COVID-19: Initiation – 4Q21\nTNX-1800:          Phase 1 trial for COVID-19 Vaccine: Initiation – 1H22\nInterim Analysis for RALLY Trial in 3Q21; Topline Results in 1Q22\nTonix is currently conducting the Phase 3 RALLY trial, a double blind, randomized, placebo controlled trial designed to evaluate the safety and efficacy of TNX-102 SL in patients with fibromyalgia (FM) (NCT04508621). It is similar in design to the Phase 3 RELIEF trial, which the company announced positive results for in December 2020, but with an additional 200 patients. The RELIEF trial showed that the 5.6 mg dose of TNX-102 SL achieved statistically significant pain reduction over placebo at Week 14 (P=0.01). For an overview of those results, see our report here. \nIn March 2021, Tonix announced that 50 percent of the planned total number of participants had been randomized in the RALLY trial and an interim analysis will take place after the 14-week treatment period has been completed. There are four potential outcomes from the interim analysis:\n1)   Stop the study early for success\n2)   Continue to enroll the study as planned\n3)   Continue to enroll the study but increase the total number of participants\n4)   Stop the study for futility\nWe estimate the result of the interim analysis will be available in the third quarter of 2021 and topline results for the full trial will be available in the first quarter of 2022. Positive results for the RALLY trial would put Tonix in a position to potentially file an NDA in 2022. \nTreating FM represents a substantial potential market opportunity. There are currently three FDA approved FM treatments; Lyrica®, Cymbalta®, and Savella®. Peak sales for both Lyrica and Cymbalta were $5 billion each for all indications (estimated approximately $1 billion each for FM), while Savella had peak sales in FM of approximately $100 million (EvaluatePharma). Lyrica and Cymbalta are both off patent, and Savella will lose patent protection in January 2023, however with each of those therapies having undesirable side effects and a lack of efficacy for a number of patients (50% of FM patients switch or discontinue therapy after 12 months), an effective therapy with a tolerable side effect profile is likely to take significant market share.\nTNX-1300 Update\nWe anticipate Tonix initiating a Phase 2 clinical trial of TNX-1300, a double mutant cocaine esterase, for the treatment of cocaine intoxication before the end of the third quarter of 2021. Tonix licensed the asset in May 2019 from Columbia University, which has breakthrough therapy designation from the U.S. FDA. \nTNX-1300 is a recombinant enzyme derived from the cocE gene of a Rhodococcus species that utilizes cocaine as a sole source of carbon and nitrogen (Bresler et al., 2000). The degradation of cocaine by the enzyme is shown in the following figure.\n\nThe CocE enzyme was tested in a rat model of cocaine toxicity to determine if it could protect the animals from cocaine-induced lethality (Cooper et al., 2006). The following chart shows that administration of increasing concentrations of CocE (CE) 1 minute before a lethal 180 mg/kg IP dose of cocaine results in increasing protection from cocaine-induced lethality (shown as “percent affected”). In fact, it required a 1000 mg/kg dose of cocaine to overcome the protective effects of 1 mg CocE (LD50 for IP dose is 70 mg/kg cocaine). BChe (butyrylcholinesterase) is an endogenous human esterase that also degrades cocaine into benzoic acid and ecgonine methyl ester, however its catalytic efficiency is much lower than CocE (Xie et al., 1999), and as shown in the following figure it is not nearly as efficient at protecting animals from a lethal dose of cocaine.\n\nOne of the issues with the native CocE enzyme is that its half-life is only a few minutes at physiological temperature (37ºC) (Cooper et al., 2006). Thus, a study was performed to develop thermostable variants of CocE using a computational approach along with in vitro and in vivo studies (Gao et al., 2009). A variant was identified with two amino acid substitutions (T172R/G173Q) that resulted in increased stability at 37ºC. The following figure shows that the double mutant CocE enzyme retains more of its activity at 37ºC for a longer period of time compared to the wild-type enzyme or the enzymes with one or the other mutations. \n\nThe double mutant CocE enzyme (then called RBP-8000, now TNX-1300) was evaluated in a Phase 2 clinical trial conducted by Reckitt Benckiser Pharmaceuticals, the previous licensee to the product (NCT01846481). It was a double blind, placebo controlled, randomized, four-sequence, two-period cross-over study. Subjects were non-treatment seekers with a DSM-IV diagnosis of cocaine abuse. During the study period, subjects were given an IV infusion of 50 mg of cocaine over 10 minutes followed by TNX-1300 (100 mg or 200 mg) or matching placebo one minute after completion of the cocaine infusion. Outcomes included pharmacokinetics of both cocaine and TNX-1300 along with any effect by TNX-1300 on cocaine-induced physiological changes (Nasser et al., 2014).\nA total of 29 subjects were randomized in the trial. Safety results showed that no anti-TNX-1300 antibodies were detected in any of the subjects at any time point. In addition, there were no clinically significant abnormalities in vital signs, clinical laboratory markers, or physical examinations. A total of seven subjects reported treatment-emergent adverse events that were considered related to treatment with any study drug, with most being assessed as mild in severity. Of note, vital signs of subjects treated with TNX-1300 returned to or below baseline earlier than subjects that received placebo, as shown in the following figure. \n\nPlasma cocaine rapidly decreased following administration of TNX-1300, with a 90% drop of peak plasma cocaine concentrations within two minutes and a 95% decline in plasma cocaine exposure. The 200 mg dose of TNX-1300 produced a longer-lasting effect on cocaine pharmacokinetics compared to the 100 mg dose. These preliminary results fully support the continued develop of TNX-1300 as a treatment for cocaine intoxication.\nTNX-1900 Update\nTonix licensed TNX-1900, a proprietary, patented enhanced formulation of intranasally administered oxytocin for the treatment of chronic migraine and craniofacial pain, in June 2020. We anticipate the company initiating a Phase 2 clinical trial for the prophylactic treatment of chronic migraine in the third quarter of 2021. \nA migraine is a headache that can cause severe pain, can last up to 72 hours, has a pulsing quality, and may be associated with nausea, vomiting, phonophobia, or photophobia. Approximately one billion individuals in the world suffer from migraine headaches (GBD 2016 Headache Collaborators). In the U.S., migraines affect approximately 72 million individuals (Gooch et al., 2017). Chronic migraines, which are defined as having a headache at least 15 times a month for three months, are less common (1-5% of migraine sufferers). While not a fatal condition, migraines still contribute to a significant decrease in quality of life and the total estimated cost of all migraine headaches is approximately $78 billion per year (Gooch et al., 2017). \nMigraine treatments are classified as abortive (intended to stop a migraine once it begins) or prophylactic (decrease the frequency and/or severity of migraines). Abortive treatments include triptans and ditans (which specifically target serotonin receptors), over the counter medications (that typically include some combination of a nonsteroidal anti-inflammatory drug (NSAID), acetaminophen, and/or caffeine), ergots, and small molecule calcitonin gene-related peptide (CGRP) antagonists. \nAntibodies that target the interaction of CGRP with its receptor represent the newest class of prophylactic treatments and include Aimovig (erenumab), which targets the CGRP receptor, and Ajovy (fremanezumab), Emgality (galcanezumab), and Vyepti (eptinezumab), which each target CGRP itself. These drugs generated approximately $1 billion in sales in 2020, and are estimated to generate 2026 sales of $4 billion (EvaluatePharma). A summary of their results in Phase 3 clinical trials is shown in the following table.\n\nEach of the CGRP-directed antibody treatments are administered as subcutaneous injections or infusions on a monthly or once every three months schedule. Side effects associated with CGRP antibodies are generally mild or moderate, with redness and/or pain at injection site the most common, although due to a number of core systems that CGRP is involved in there are a number of theoretical long-term adverse effects that may arise once the data (≥10 years) is available, including CGRP’s role in hypertension, wound healing, and insulin levels (Robbins, 2020).\nOxytocin in Migraine\nWhile the exact cause of migraines remains to be elucidated, it appears to be associated with the hypothalamus and its communication with the spinal trigeminal nuclei and sensory trigeminovascular system, thus neuromodulators that target the trigeminal pathway could prove effective in migraines.\nOxytocin is a nine amino acid peptide hormone that is involved in a wide array of biological processes, including learning and memory, anxiety, addiction, feeding behavior, maternal behavior, and processing of social information (Cilz et al., 2019). A review of the available literature showed that in 29/33 animal studies oxytocin increased “pain” tolerance (Rash et al., 2014), which suggests it may act as an analgesic. Circumstantial evidence shows that oxytocin may be an effective migraine treatment based on the fact that increased oxytocin levels in pregnancy and during breastfeeding correlates with decreased migraine occurrence (Hoshiyama et al., 2012) and women who suffer from migraines report that sex (which results in a surge in oxytocin levels) provides at least temporary relief from the condition (Evans et al., 2001). \nWhile the potential for oxytocin as a treatment for migraine headaches appears promising, getting oxytocin to the trigeminal system is challenging due to the fact that: 1) oxytocin is a small peptide that is broken down almost immediately in the gastrointestinal system; and 2) its half-life in the blood stream is very short (3-5 min) with only limited ability to cross the blood-brain barrier, thus eliminating the availability of oral or parenteral administration. But delivered intranasally, oxytocin permeates the nasal mucosa and is transported along the trigeminal nerve pathway to the trigeminal ganglion where it can inhibit release along trigeminal neurons that synapse within the lining of the dura mater and inhibit CGRP release. Additionally, the most direct way to bypass the blood brain barrier and gain access to the CNS could be nasal administration along olfactory and trigeminal pathways to the brain (Dhuria et al., 2010).\nMultiple preclinical studies have examined the potential for oxytocin as a migraine treatment. Oxytocin receptors are present in rat trigeminal neurons, and the vast majority of neurons that express oxytocin receptors also express CGRP (Tzabazis et al., 2016). Intranasal administration of radiolabeled oxytocin in rats results in a very high concentration of oxytocin in all three branches of the trigeminal nerve and trigeminal ganglion (Tzabazis et al., 2017). Administration of nitroglycerin triggers migraine headaches in patients (Sances et al., 2004), thus intraperitoneal injection of nitroglycerin is utilized in a rat model of migraine (Ma et al., 2008). This model results in expression of C-fos in multiple trigeminal neurons (a marker for trigeminal nerve activation), however pre-treatment with intranasal oxytocin markedly reduces the expression of C-fos, thus pointing to a potential role of oxytocin in preventing pain transmission. \nA Phase 2 clinical trial of intranasal oxytocin was previously conducted by Trigemina, Inc., from which Tonix acquired TNX-1900 in June 2020. This was a double blind, placebo controlled trial in 218 mostly female migraine sufferers (143 on oxytocin; 75 on placebo) and was conducted in Chile, Australia, and New Zealand (NCT01839149). The trial consisted of a 28-day “run-in” period to establish a baseline of migraine days followed by 56 days of “as needed” dosing with either intranasal oxytocin or placebo. Results showed that while intranasal oxytocin was well tolerated, the study did not meet the primary endpoint of a reduction in migraine headache days from baseline. This was mostly due to an extremely high placebo response rate at the clinical sites in Chile, which was 74%, while subjects from New Zealand and Australia experienced a normal placebo response and showed a statistically significant difference between active and placebo groups (Tzabazis et al., 2017). \nBased on results of preclinical studies demonstrating enhanced analgesic activity of oxytocin mediated by the oxytocin receptor in the presence of magnesium, Trigemina developed a proprietary, potentiated formulation of oxytocin containing magnesium. Tonix acquired the intellectual property for this formulation and plans to advance it first in the study of chronic migraine. \nTo follow up on the results of the prior Phase 2 trial, we anticipate Tonix conducting a classic preventative migraine Phase 2 trial of TNX-1900, which is the potentiated formulation of intranasal oxytocin, for the prophylactic treatment of chronic migraine. We expect the trial to be similarly designed to the previous Phase 2 trial with a 28-day baseline period followed by 84 days of dosing. \nThe market opportunity in treating chronic migraine is large. We estimate approximately two million Americans suffer from chronic migraine and even taking a single digit percentage of this population could result in peak revenue of approximately $500 million. \nLicenses Anti-Viral Compound as Potential COVID-19 Treatment\nIn April 2021, Tonix announced an exclusive worldwide license agreement with OyaGen, Inc. for an antiviral compound, TNX-3500 (sangivamycin, formerly OYA1), for the treatment of COVID-19 and possibly other viral diseases. Sangivamycin is a natural product that was originally isolated from Streptomyces rimosus and studied in the 1960’s by the National Cancer Institute (NCI) as a potential cancer therapeutic. Due to lack of efficacy the drug did not advance as an anti-cancer therapy but it did show good safety and tolerability in those trials. \nA recent study identified sangivamycin as an inhibitor of Ebola virus replication, and surprisingly it also inhibited the replication of Marburg virus, Lassa virus, cowpox virus, and vaccinia virus (Bennett et al., 2020). OyaGen followed up these results with a collaborative research project with the National Institutes of Allergy and Infectious Diseases Integrated Research Facility (NIAID-IRF) to study the effect of sangivamycin on the replication of SARS-CoV-2. Unpublished results show that the compound has strong dose-dependent antiviral activity against SARS-CoV-2 and was approximately 65 times more potent than remdesivir (Veklury®). In addition, combination treatment with sangivamycin and remdesivir show additive activity against SARS-CoV-2. \nTonix will be conducting further preclinical studies to test the safety and efficacy of sangivamycin as a treatment for COVID-19 and we anticipate an update on this program later this year.\nFinancial Update\nOn May 10, 2021, Tonix announced financial results for the first quarter of 2021. As expected, the company did not report any revenues for the first quarter of 2021. Net loss available to common shareholders for the first quarter of 2021 was $20.7 million, or $0.07 per share, compared to a net loss available to common shareholders of $9.0 million, or $0.37 per share, for the first quarter of 2020. The weighted average common shares outstanding for the first quarter of 2021 were approximately 290.1 million compared to approximately 24.0 million in the first quarter of 2020.\nR&D expenses for the first quarter of 2021 were $15.3 million, compared to $4.7 million for the first quarter of 2020. The increase was primarily due to the timing of milestones related to the Phase 3 RELIEF trial along with preparative activities for the initiation of Phase 2 trials of TNX-1300, TNX-1900, and TNX-601 CR. G&A expenses for the first quarter of 2021 were $5.4 million, compared to $2.6 million for the first quarter of 2020. The increase was primarily due to increased reporting expenses, patent prosecution and maintenance costs, and an increase in salaries. \nAs of March 31, 2021, Tonix had approximately $164.2 million in cash and cash equivalents. This was due in part to the company raising approximately $110 million from previously announced securities purchase agreements during the first quarter of 2021. As of May 7, 2021, Tonix had approximately 326.5 million common shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of approximately 350.1 million. \nConclusion\nTonix is in a very strong financial position with $164.2 million in cash and cash equivalents, which will help the company advance the multiple pipeline candidates into and through the clinic. The most immediate inflection point will be the interim analysis for the RALLY trial, which we anticipate in the third quarter of 2021. Topline results for that trial should be announced in the first quarter of 2022, and if positive will allow for the company to file an NDA likely in 2022. In addition, the company will be initiating another Phase 3 trial for TNX-102 SL in PTSD in police in Kenya in the third quarter of 2021 and potentially three Phase 2 trials for TNX-1300, TNX-1900, and TNX-601 CR before the end of 2021. Since it will be entering the clinic in the third quarter of 2021, we have incorporated TNX-1900 into our model, which has increased our valuation to $4.50 per share. \nSUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. \n \nDISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1043,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":118096422,"gmtCreate":1622706423766,"gmtModify":1622706423766,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TOUR\">$途牛(TOUR)$</a>来吧，小板凳已经搬好了","listText":"<a href=\"https://laohu8.com/S/TOUR\">$途牛(TOUR)$</a>来吧，小板凳已经搬好了","text":"$途牛(TOUR)$来吧，小板凳已经搬好了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/118096422","isVote":1,"tweetType":1,"viewCount":1735,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3474365319245602","authorId":"3474365319245602","name":"多多侠","avatar":"https://static.laohu8.com/2340943a6cd3d030f3be44e933af416d","crmLevel":2,"crmLevelSwitch":0},"content":"要么一飞冲天，要么完犊子","text":"要么一飞冲天，要么完犊子","html":"要么一飞冲天，要么完犊子"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":134960755,"gmtCreate":1622201009177,"gmtModify":1622201009177,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"中报期，是不是可以各种炒财报了","listText":"中报期，是不是可以各种炒财报了","text":"中报期，是不是可以各种炒财报了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/134960755","isVote":1,"tweetType":1,"viewCount":1216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":324227696,"gmtCreate":1615996732415,"gmtModify":1703496214302,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"哥，以后我就跟你干了","htmlText":"今天，小区对面那美女给我打了个微信电话，约我去离家10km的湿地公园，说是谈一些重要的事儿！当然我如约而至，这几天没见变化太大了吧，人群中我一眼就认出了她。她身材高挑，皮肤白净，大眼睛裡透出少女的稚气！你有什么事儿嘛，非得在这说，我家里的汤还熬着呢。看见我来了，她却沉默了，我疑惑的问了她，啥事你倒是说呀，从她的诉说中得知股票又亏损了，次新板块履创新低........ 她满仓被套。“首先啊，借钱补仓别找我，最近我都被套的死死的。动也动不了，这一点我得事先申明。”她看我如此直接，便坐下来把自己的经历详详细细地叙述给我听，说着说着，忍不住她眼泪就不由自主流了下来。看得出来，她是对股票动了真感情，因为家庭的不幸，她只能寄托于股票上面了。这个时候她的内心是最脆弱的，急需得到安慰和鼓励。当时我的内心很矛盾，此时乘虚而入也确实有点卑鄙.我立马说出了一连串的号码：<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a><a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>信誓旦旦的说道，这些你随便买，翻倍没有问题，这时的她 泪眼婆娑，如梨花带雨般惹人心痛，我身不由己的拿面巾纸替她轻轻地擦去泪珠。她竟然就势趴到我肩膀上痛哭不止。我温柔地，轻轻地拍着她的背，就像哄小孩子不停地哄着她。慢慢地等到她哭够了，才小心翼翼地捧起她娇小的脸庞，仔细将这张漂亮的小脸擦乾净。睁开她那湿漉漉的大眼睛，用一种期待的眼神看着我。那是一种伤心后急需抚慰的目光，我热血上涌，心跳加剧，内心激烈地斗争着，一双","listText":"今天，小区对面那美女给我打了个微信电话，约我去离家10km的湿地公园，说是谈一些重要的事儿！当然我如约而至，这几天没见变化太大了吧，人群中我一眼就认出了她。她身材高挑，皮肤白净，大眼睛裡透出少女的稚气！你有什么事儿嘛，非得在这说，我家里的汤还熬着呢。看见我来了，她却沉默了，我疑惑的问了她，啥事你倒是说呀，从她的诉说中得知股票又亏损了，次新板块履创新低........ 她满仓被套。“首先啊，借钱补仓别找我，最近我都被套的死死的。动也动不了，这一点我得事先申明。”她看我如此直接，便坐下来把自己的经历详详细细地叙述给我听，说着说着，忍不住她眼泪就不由自主流了下来。看得出来，她是对股票动了真感情，因为家庭的不幸，她只能寄托于股票上面了。这个时候她的内心是最脆弱的，急需得到安慰和鼓励。当时我的内心很矛盾，此时乘虚而入也确实有点卑鄙.我立马说出了一连串的号码：<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a><a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>信誓旦旦的说道，这些你随便买，翻倍没有问题，这时的她 泪眼婆娑，如梨花带雨般惹人心痛，我身不由己的拿面巾纸替她轻轻地擦去泪珠。她竟然就势趴到我肩膀上痛哭不止。我温柔地，轻轻地拍着她的背，就像哄小孩子不停地哄着她。慢慢地等到她哭够了，才小心翼翼地捧起她娇小的脸庞，仔细将这张漂亮的小脸擦乾净。睁开她那湿漉漉的大眼睛，用一种期待的眼神看着我。那是一种伤心后急需抚慰的目光，我热血上涌，心跳加剧，内心激烈地斗争着，一双","text":"今天，小区对面那美女给我打了个微信电话，约我去离家10km的湿地公园，说是谈一些重要的事儿！当然我如约而至，这几天没见变化太大了吧，人群中我一眼就认出了她。她身材高挑，皮肤白净，大眼睛裡透出少女的稚气！你有什么事儿嘛，非得在这说，我家里的汤还熬着呢。看见我来了，她却沉默了，我疑惑的问了她，啥事你倒是说呀，从她的诉说中得知股票又亏损了，次新板块履创新低........ 她满仓被套。“首先啊，借钱补仓别找我，最近我都被套的死死的。动也动不了，这一点我得事先申明。”她看我如此直接，便坐下来把自己的经历详详细细地叙述给我听，说着说着，忍不住她眼泪就不由自主流了下来。看得出来，她是对股票动了真感情，因为家庭的不幸，她只能寄托于股票上面了。这个时候她的内心是最脆弱的，急需得到安慰和鼓励。当时我的内心很矛盾，此时乘虚而入也确实有点卑鄙.我立马说出了一连串的号码：$Synthetic Biologics Inc(SYN)$$Color Star Technology Co. Ltd(CSCW)$$Castor Maritime, Inc.(CTRM)$信誓旦旦的说道，这些你随便买，翻倍没有问题，这时的她 泪眼婆娑，如梨花带雨般惹人心痛，我身不由己的拿面巾纸替她轻轻地擦去泪珠。她竟然就势趴到我肩膀上痛哭不止。我温柔地，轻轻地拍着她的背，就像哄小孩子不停地哄着她。慢慢地等到她哭够了，才小心翼翼地捧起她娇小的脸庞，仔细将这张漂亮的小脸擦乾净。睁开她那湿漉漉的大眼睛，用一种期待的眼神看着我。那是一种伤心后急需抚慰的目光，我热血上涌，心跳加剧，内心激烈地斗争着，一双","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":377,"commentSize":139,"repostSize":13,"link":"https://laohu8.com/post/324227696","isVote":1,"tweetType":1,"viewCount":35448,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3483701686535019","authorId":"3483701686535019","name":"Seanxiao","avatar":"https://static.tigerbbs.com/3d3af5d5d67887c89e6cf127e35ae822","crmLevel":2,"crmLevelSwitch":0},"content":"言情小说吗。是不是还有后续[得意][得意][得意][得意]","text":"言情小说吗。是不是还有后续[得意][得意][得意][得意]","html":"言情小说吗。是不是还有后续[得意][得意][得意][得意]"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":327963278,"gmtCreate":1616051551394,"gmtModify":1703496891893,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"忍一下，真的不疼！","htmlText":"自从20210204入金以来，短短的一个月，历经了“暴富”和“血亏”，可谓是尝尽股市冷暖，且听我娓娓道来：基于在美股市场暴富的远大理想，入金伊始，夜以继日的翻阅各种帖子，以便自己尽快的加入美股的淘金队伍，功夫不费有心人，茫茫股群中我发现了那束光<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a>，这是我买的第一支股票，当晚便冲高到220%，最终盈利150%。如此我就更加有动力的去研究毛票了，白天A股晚上美股，整个人都不好了，然而付出终于又迎来了第二次“回报”，大年夜<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>给我送了一份大礼，再次冲高盈利200%+。上面是我两次“暴富”经历，如此短时间内轻易的“暴富”让我把运气当成了实力，我飘了 。某一个雨夜，我追高了某支股票，也许是老天早有预兆，电闪雷鸣，那晚我喝醉了，没有设止损单，第二天酒意未散的我拿起手机瞬间便清醒了，浮亏50%+，无奈忍痛割肉。接下来因为美债利率上涨，美指连续暴跌，小散的思维让我很快“抄底”完毕，接下来只能望“底”兴叹，随后久违的反弹来了，说时迟那时快，我以掩耳不及盗铃响叮当之势，18.2出了老虎<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>（成本19.3），然后卖空了老虎，正当自己洋洋得意之际，老虎一改颓太冲上22.5，我“及时”买入止损，随后一幕大家也想到了，老虎回跌至19.2，一阵操作猛如虎，拍断了大腿。另一支票是火箭公司，42的空单，开盘39处一个小反弹把我洗出去了，随后股价将至24，另外一只腿也拍断了，就差2分钟就可以盈利40%。还有一些骚操作就不说了，简直令人叹为观止。想必我的“光辉”历史，也是很多韭菜的历史，很多前辈","listText":"自从20210204入金以来，短短的一个月，历经了“暴富”和“血亏”，可谓是尝尽股市冷暖，且听我娓娓道来：基于在美股市场暴富的远大理想，入金伊始，夜以继日的翻阅各种帖子，以便自己尽快的加入美股的淘金队伍，功夫不费有心人，茫茫股群中我发现了那束光<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a>，这是我买的第一支股票，当晚便冲高到220%，最终盈利150%。如此我就更加有动力的去研究毛票了，白天A股晚上美股，整个人都不好了，然而付出终于又迎来了第二次“回报”，大年夜<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>给我送了一份大礼，再次冲高盈利200%+。上面是我两次“暴富”经历，如此短时间内轻易的“暴富”让我把运气当成了实力，我飘了 。某一个雨夜，我追高了某支股票，也许是老天早有预兆，电闪雷鸣，那晚我喝醉了，没有设止损单，第二天酒意未散的我拿起手机瞬间便清醒了，浮亏50%+，无奈忍痛割肉。接下来因为美债利率上涨，美指连续暴跌，小散的思维让我很快“抄底”完毕，接下来只能望“底”兴叹，随后久违的反弹来了，说时迟那时快，我以掩耳不及盗铃响叮当之势，18.2出了老虎<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>（成本19.3），然后卖空了老虎，正当自己洋洋得意之际，老虎一改颓太冲上22.5，我“及时”买入止损，随后一幕大家也想到了，老虎回跌至19.2，一阵操作猛如虎，拍断了大腿。另一支票是火箭公司，42的空单，开盘39处一个小反弹把我洗出去了，随后股价将至24，另外一只腿也拍断了，就差2分钟就可以盈利40%。还有一些骚操作就不说了，简直令人叹为观止。想必我的“光辉”历史，也是很多韭菜的历史，很多前辈","text":"自从20210204入金以来，短短的一个月，历经了“暴富”和“血亏”，可谓是尝尽股市冷暖，且听我娓娓道来：基于在美股市场暴富的远大理想，入金伊始，夜以继日的翻阅各种帖子，以便自己尽快的加入美股的淘金队伍，功夫不费有心人，茫茫股群中我发现了那束光$极光(JG)$，这是我买的第一支股票，当晚便冲高到220%，最终盈利150%。如此我就更加有动力的去研究毛票了，白天A股晚上美股，整个人都不好了，然而付出终于又迎来了第二次“回报”，大年夜$Sundial Growers Inc.(SNDL)$给我送了一份大礼，再次冲高盈利200%+。上面是我两次“暴富”经历，如此短时间内轻易的“暴富”让我把运气当成了实力，我飘了 。某一个雨夜，我追高了某支股票，也许是老天早有预兆，电闪雷鸣，那晚我喝醉了，没有设止损单，第二天酒意未散的我拿起手机瞬间便清醒了，浮亏50%+，无奈忍痛割肉。接下来因为美债利率上涨，美指连续暴跌，小散的思维让我很快“抄底”完毕，接下来只能望“底”兴叹，随后久违的反弹来了，说时迟那时快，我以掩耳不及盗铃响叮当之势，18.2出了老虎$老虎证券(TIGR)$（成本19.3），然后卖空了老虎，正当自己洋洋得意之际，老虎一改颓太冲上22.5，我“及时”买入止损，随后一幕大家也想到了，老虎回跌至19.2，一阵操作猛如虎，拍断了大腿。另一支票是火箭公司，42的空单，开盘39处一个小反弹把我洗出去了，随后股价将至24，另外一只腿也拍断了，就差2分钟就可以盈利40%。还有一些骚操作就不说了，简直令人叹为观止。想必我的“光辉”历史，也是很多韭菜的历史，很多前辈","images":[],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":35,"commentSize":39,"repostSize":4,"link":"https://laohu8.com/post/327963278","isVote":1,"tweetType":1,"viewCount":18193,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3478146770836426","authorId":"3478146770836426","name":"weidudu","avatar":"https://static.laohu8.com/c7a6392d362cbf0eeec660d84e88646f","crmLevel":2,"crmLevelSwitch":0},"content":"你真是个才华和美貌并存的小可爱[贱笑]","text":"你真是个才华和美貌并存的小可爱[贱笑]","html":"你真是个才华和美貌并存的小可爱[贱笑]"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":348581171,"gmtCreate":1617941298093,"gmtModify":1617971590606,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"最近身边很多股票，尤其是毛票腰斩的很多，很多人过分情绪化，此时此刻我想借用一句话送给大家“不要为已经过去的事过分苛责自己，更别把时间浪费在懊悔和委屈上。不必太纠结于当下，也不必太忧虑未来。张弛有度，才能为持续的成长不断蓄力。”如果你现在倒下你就彻底输了<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/XL\">$XL Fleet Corp(XL)$</a><a href=\"https://laohu8.com/S/TNXP\">$Tonix Pharmaceuticals Holding Co(TNXP)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>我们就像下图中的人一样，需要慢慢等待，潮水会退去，旭日终将东升，愿大家发财[正经]&nbsp;我发现我tm最近越来越能扯淡了，有木有","listText":"最近身边很多股票，尤其是毛票腰斩的很多，很多人过分情绪化，此时此刻我想借用一句话送给大家“不要为已经过去的事过分苛责自己，更别把时间浪费在懊悔和委屈上。不必太纠结于当下，也不必太忧虑未来。张弛有度，才能为持续的成长不断蓄力。”如果你现在倒下你就彻底输了<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/XL\">$XL Fleet Corp(XL)$</a><a href=\"https://laohu8.com/S/TNXP\">$Tonix Pharmaceuticals Holding Co(TNXP)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>我们就像下图中的人一样，需要慢慢等待，潮水会退去，旭日终将东升，愿大家发财[正经]&nbsp;我发现我tm最近越来越能扯淡了，有木有","text":"最近身边很多股票，尤其是毛票腰斩的很多，很多人过分情绪化，此时此刻我想借用一句话送给大家“不要为已经过去的事过分苛责自己，更别把时间浪费在懊悔和委屈上。不必太纠结于当下，也不必太忧虑未来。张弛有度，才能为持续的成长不断蓄力。”如果你现在倒下你就彻底输了$Synthetic Biologics Inc(SYN)$$Castor Maritime, Inc.(CTRM)$$XL Fleet Corp(XL)$$Tonix Pharmaceuticals Holding Co(TNXP)$$Color Star Technology Co. Ltd(CSCW)$我们就像下图中的人一样，需要慢慢等待，潮水会退去，旭日终将东升，愿大家发财[正经] 我发现我tm最近越来越能扯淡了，有木有","images":[{"img":"https://static.tigerbbs.com/a6b0c3871e1a7796de557cd9616923dc","width":"683","height":"1024"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":23,"commentSize":17,"repostSize":0,"link":"https://laohu8.com/post/348581171","isVote":1,"tweetType":1,"viewCount":11094,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3557441995443761","authorId":"3557441995443761","name":"Hbwen","avatar":"https://static.tigerbbs.com/01d25e0cc29a67de031bdf2427f8c2e6","crmLevel":2,"crmLevelSwitch":0},"content":"被套了几支","text":"被套了几支","html":"被套了几支"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":135139971,"gmtCreate":1622140092993,"gmtModify":1622258062264,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"割肉<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a>建仓<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a><a href=\"https://laohu8.com/S/RAAS\">$容联云(RAAS)$</a><a href=\"https://laohu8.com/S/TOUR\">$途牛(TOUR)$</a><a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$</a>","listText":"割肉<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a>建仓<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a><a href=\"https://laohu8.com/S/RAAS\">$容联云(RAAS)$</a><a href=\"https://laohu8.com/S/TOUR\">$途牛(TOUR)$</a><a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$</a>","text":"割肉$Synthetic Biologics Inc(SYN)$建仓$极光(JG)$$容联云(RAAS)$$途牛(TOUR)$$箩筐技术(LKCO)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":18,"commentSize":19,"repostSize":0,"link":"https://laohu8.com/post/135139971","isVote":1,"tweetType":1,"viewCount":7382,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3548933020546428","authorId":"3548933020546428","name":"tonychown","avatar":"https://static.tigerbbs.com/3c98ce006517da29c1850bcb1369b8fc","crmLevel":3,"crmLevelSwitch":0},"content":"真有勇气 [强]","text":"真有勇气 [强]","html":"真有勇气 [强]"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":340196966,"gmtCreate":1617351084755,"gmtModify":1617631681766,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>，现在大家都知道下个月要到5块了","listText":"<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>，现在大家都知道下个月要到5块了","text":"$Synthetic Biologics Inc(SYN)$$Castor Maritime, Inc.(CTRM)$$Color Star Technology Co. Ltd(CSCW)$，现在大家都知道下个月要到5块了","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":6,"commentSize":24,"repostSize":0,"link":"https://laohu8.com/post/340196966","isVote":1,"tweetType":1,"viewCount":6770,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3572443534577546","authorId":"3572443534577546","name":"大黄是只猫","avatar":"https://static.tigerbbs.com/deddc73503c75dc10a55831a77c2fafa","crmLevel":1,"crmLevelSwitch":0},"content":"庄家最爱你这样的韭菜","text":"庄家最爱你这样的韭菜","html":"庄家最爱你这样的韭菜"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":371587799,"gmtCreate":1618961307511,"gmtModify":1619012247913,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>再杀一波可能要反弹了，还没到上月前低，稳住，等等破了前低还跌就真的要准备跑路了","listText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>再杀一波可能要反弹了，还没到上月前低，稳住，等等破了前低还跌就真的要准备跑路了","text":"$Castor Maritime, Inc.(CTRM)$$Synthetic Biologics Inc(SYN)$$Color Star Technology Co. Ltd(CSCW)$再杀一波可能要反弹了，还没到上月前低，稳住，等等破了前低还跌就真的要准备跑路了","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":20,"commentSize":16,"repostSize":0,"link":"https://laohu8.com/post/371587799","isVote":1,"tweetType":1,"viewCount":6668,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575453506994802","authorId":"3575453506994802","name":"老鹰飞翔","avatar":"https://static.tigerbbs.com/3033df8d5693e4a9045f973d88b65f87","crmLevel":1,"crmLevelSwitch":0},"content":"大家做好退市准备吧","text":"大家做好退市准备吧","html":"大家做好退市准备吧"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":354403666,"gmtCreate":1617193436155,"gmtModify":1617196668940,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>听（潜伏）说下个月要上5块钱[贱笑]&nbsp;[贱笑]&nbsp;[贱笑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>听（潜伏）说下个月要上5块钱[贱笑]&nbsp;[贱笑]&nbsp;[贱笑]&nbsp;","text":"$Castor Maritime, Inc.(CTRM)$$Synthetic Biologics Inc(SYN)$$Color Star Technology Co. Ltd(CSCW)$听（潜伏）说下个月要上5块钱[贱笑] [贱笑] [贱笑]","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":21,"commentSize":15,"repostSize":1,"link":"https://laohu8.com/post/354403666","isVote":1,"tweetType":1,"viewCount":10102,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3498032310834282","authorId":"3498032310834282","name":"TheWorld","avatar":"https://static.tigerbbs.com/1bf08ecbcdb9e3ebc88cbcf70a1731e2","crmLevel":2,"crmLevelSwitch":0},"content":"[捂脸]先问过大盘答应不","text":"[捂脸]先问过大盘答应不","html":"[捂脸]先问过大盘答应不"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":358725551,"gmtCreate":1616733115973,"gmtModify":1616764076716,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"股票翻倍之后…","htmlText":"比如说你去赌场赌钱，带着一万块钱进去，然后赢了一万块钱，这时候很多人都会产生一个心理现象，就是把带进去的那一万块钱放到一边，把赢了的这一万块钱放在桌子上作为赌资继续赌博。很多人的心理活动是这样子的，带进来的一万块是我的辛苦钱、血汗钱，我先放起来，保证它的安全；赢了的这一万块钱其实是白来的，我即便输了也没什么大不了。怎么样？听起来是不是很有道理？很多人是不是都会有这样的心理活动？<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a><a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>欢迎大家对号入座[开心]&nbsp;[开心]&nbsp;[开心]&nbsp;","listText":"比如说你去赌场赌钱，带着一万块钱进去，然后赢了一万块钱，这时候很多人都会产生一个心理现象，就是把带进去的那一万块钱放到一边，把赢了的这一万块钱放在桌子上作为赌资继续赌博。很多人的心理活动是这样子的，带进来的一万块是我的辛苦钱、血汗钱，我先放起来，保证它的安全；赢了的这一万块钱其实是白来的，我即便输了也没什么大不了。怎么样？听起来是不是很有道理？很多人是不是都会有这样的心理活动？<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a><a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a><a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a>欢迎大家对号入座[开心]&nbsp;[开心]&nbsp;[开心]&nbsp;","text":"比如说你去赌场赌钱，带着一万块钱进去，然后赢了一万块钱，这时候很多人都会产生一个心理现象，就是把带进去的那一万块钱放到一边，把赢了的这一万块钱放在桌子上作为赌资继续赌博。很多人的心理活动是这样子的，带进来的一万块是我的辛苦钱、血汗钱，我先放起来，保证它的安全；赢了的这一万块钱其实是白来的，我即便输了也没什么大不了。怎么样？听起来是不是很有道理？很多人是不是都会有这样的心理活动？$Takung Art Co., Ltd.(TKAT)$$Sundial Growers Inc.(SNDL)$$Color Star Technology Co. Ltd(CSCW)$欢迎大家对号入座[开心] [开心] [开心]","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":17,"commentSize":16,"repostSize":0,"link":"https://laohu8.com/post/358725551","isVote":1,"tweetType":1,"viewCount":9557,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3554459295496557","authorId":"3554459295496557","name":"战神白胜","avatar":"https://static.tigerbbs.com/49eadb9733ef207dd9f1221e2410fd30","crmLevel":2,"crmLevelSwitch":0},"content":"不 很多人想的是两万变四万","text":"不 很多人想的是两万变四万","html":"不 很多人想的是两万变四万"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":359398364,"gmtCreate":1616337042058,"gmtModify":1616403809198,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"大家有没有和我一样，对周一既期盼，又带着些许忐忑不安，[开心]&nbsp;[开心]&nbsp;<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a><a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a>","listText":"大家有没有和我一样，对周一既期盼，又带着些许忐忑不安，[开心]&nbsp;[开心]&nbsp;<a href=\"https://laohu8.com/S/JG\">$极光(JG)$</a><a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a>","text":"大家有没有和我一样，对周一既期盼，又带着些许忐忑不安，[开心] [开心] $极光(JG)$$老虎证券(TIGR)$$Synthetic Biologics Inc(SYN)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":20,"commentSize":14,"repostSize":0,"link":"https://laohu8.com/post/359398364","isVote":1,"tweetType":1,"viewCount":5705,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573212809260326","authorId":"3573212809260326","name":"虚心求教","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0},"content":"jg应该还是跌","text":"jg应该还是跌","html":"jg应该还是跌"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":341373953,"gmtCreate":1617787127472,"gmtModify":1617787303578,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>加油老虎，25等你","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>加油老虎，25等你","text":"$老虎证券(TIGR)$加油老虎，25等你","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":8,"commentSize":18,"repostSize":0,"link":"https://laohu8.com/post/341373953","isVote":1,"tweetType":1,"viewCount":2042,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3554708838834221","authorId":"3554708838834221","name":"霸气威武","avatar":"https://static.tigerbbs.com/884a97d08a6f7f0246c299686e81f873","crmLevel":4,"crmLevelSwitch":1},"content":"不到五块不回头","text":"不到五块不回头","html":"不到五块不回头"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":189120082,"gmtCreate":1623248514146,"gmtModify":1623249810262,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>请叫我韭菜，第一次追高就追山顶","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>请叫我韭菜，第一次追高就追山顶","text":"$ContextLogic Inc.(WISH)$请叫我韭菜，第一次追高就追山顶","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":7,"commentSize":14,"repostSize":0,"link":"https://laohu8.com/post/189120082","isVote":1,"tweetType":1,"viewCount":2833,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575764178135145","authorId":"3575764178135145","name":"MaRo","avatar":"https://static.tigerbbs.com/8c7022bbcac13197c84f0d963050133e","crmLevel":4,"crmLevelSwitch":0},"content":"多少入的？","text":"多少入的？","html":"多少入的？"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":345411667,"gmtCreate":1618328942259,"gmtModify":1618358500676,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CAN\">$嘉楠科技(CAN)$</a>应该差不多了吧，掐指一算，14.5左右今天","listText":"<a href=\"https://laohu8.com/S/CAN\">$嘉楠科技(CAN)$</a>应该差不多了吧，掐指一算，14.5左右今天","text":"$嘉楠科技(CAN)$应该差不多了吧，掐指一算，14.5左右今天","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":8,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/345411667","isVote":1,"tweetType":1,"viewCount":3883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":105821997,"gmtCreate":1620290633419,"gmtModify":1620290633419,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$</a>我不懂这个票9号不是要停牌了，为什么还一直涨","listText":"<a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$</a>我不懂这个票9号不是要停牌了，为什么还一直涨","text":"$箩筐技术(LKCO)$我不懂这个票9号不是要停牌了，为什么还一直涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":11,"repostSize":1,"link":"https://laohu8.com/post/105821997","isVote":1,"tweetType":1,"viewCount":6744,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575245304823304","authorId":"3575245304823304","name":"暗光骑士","avatar":"https://static.tigerbbs.com/2011836142d73011289f1919ebddec29","crmLevel":1,"crmLevelSwitch":0},"content":"这上新闻还没公布哦！要上车一定要早点哦","text":"这上新闻还没公布哦！要上车一定要早点哦","html":"这上新闻还没公布哦！要上车一定要早点哦"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":374423096,"gmtCreate":1619478060515,"gmtModify":1619478060515,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a><a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CAN\">$嘉楠科技(CAN)$</a><a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$</a>最近美股行情渐好，都开始反弹了，继续努力","listText":"<a href=\"https://laohu8.com/S/CSCW\">$Color Star Technology Co. Ltd(CSCW)$</a><a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a><a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a><a href=\"https://laohu8.com/S/CAN\">$嘉楠科技(CAN)$</a><a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$</a>最近美股行情渐好，都开始反弹了，继续努力","text":"$Color Star Technology Co. Ltd(CSCW)$$Castor Maritime, Inc.(CTRM)$$Synthetic Biologics Inc(SYN)$$嘉楠科技(CAN)$$箩筐技术(LKCO)$最近美股行情渐好，都开始反弹了，继续努力","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":16,"commentSize":7,"repostSize":1,"link":"https://laohu8.com/post/374423096","isVote":1,"tweetType":1,"viewCount":4489,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573110536536197","authorId":"3573110536536197","name":"接锅侠","avatar":"https://static.tigerbbs.com/1c7f3c93c8a94eab9c5e9cf68bb06b6a","crmLevel":1,"crmLevelSwitch":0},"content":"如果合股，是不是就凉凉了","text":"如果合股，是不是就凉凉了","html":"如果合股，是不是就凉凉了"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":359677828,"gmtCreate":1616400139364,"gmtModify":1616400139364,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>被你们去月球的骗进来的，月球在哪里","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>被你们去月球的骗进来的，月球在哪里","text":"$Sundial Growers Inc.(SNDL)$被你们去月球的骗进来的，月球在哪里","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/359677828","isVote":1,"tweetType":1,"viewCount":3108,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3536537616181037","authorId":"3536537616181037","name":"西西hh","avatar":"https://static.tigerbbs.com/ae5567823bcb82a845aa7ff56b92e350","crmLevel":2,"crmLevelSwitch":0},"content":"梦里都会有的","text":"梦里都会有的","html":"梦里都会有的"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":358122030,"gmtCreate":1616674804720,"gmtModify":1616674804720,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"中美对抗，所有中概股都一样，别看了，洗洗睡了<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/FUTU\">$富途控股(FUTU)$</a><a href=\"https://laohu8.com/S/BILI\">$哔哩哔哩(BILI)$</a>","listText":"中美对抗，所有中概股都一样，别看了，洗洗睡了<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/FUTU\">$富途控股(FUTU)$</a><a href=\"https://laohu8.com/S/BILI\">$哔哩哔哩(BILI)$</a>","text":"中美对抗，所有中概股都一样，别看了，洗洗睡了$老虎证券(TIGR)$$富途控股(FUTU)$$哔哩哔哩(BILI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":4,"repostSize":1,"link":"https://laohu8.com/post/358122030","isVote":1,"tweetType":1,"viewCount":4832,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3440047170502757","authorId":"3440047170502757","name":"accelerate","avatar":"https://static.tigerbbs.com/d4c4fe2b5d189b0a66a7ad4dd28a7fc8","crmLevel":5,"crmLevelSwitch":1},"content":"这股市，过两到三个月才能看，现在任何消息都是下跌的理由","text":"这股市，过两到三个月才能看，现在任何消息都是下跌的理由","html":"这股市，过两到三个月才能看，现在任何消息都是下跌的理由"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":371586568,"gmtCreate":1618961118554,"gmtModify":1618961118554,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/FUTU\">$富途控股(FUTU)$</a>这一波老虎还有14可以买么","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/FUTU\">$富途控股(FUTU)$</a>这一波老虎还有14可以买么","text":"$老虎证券(TIGR)$$富途控股(FUTU)$这一波老虎还有14可以买么","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":8,"repostSize":0,"link":"https://laohu8.com/post/371586568","isVote":1,"tweetType":1,"viewCount":3068,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":106452032,"gmtCreate":1620141277126,"gmtModify":1620141277126,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a>5月15不成功便成仁","listText":"<a href=\"https://laohu8.com/S/SYN\">$Synthetic Biologics Inc(SYN)$</a>5月15不成功便成仁","text":"$Synthetic Biologics Inc(SYN)$5月15不成功便成仁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":8,"repostSize":0,"link":"https://laohu8.com/post/106452032","isVote":1,"tweetType":1,"viewCount":3299,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3572932824677354","authorId":"3572932824677354","name":"再见猫王","avatar":"https://static.tigerbbs.com/f8bc3a6dc6d81facc3f689ef7d816057","crmLevel":2,"crmLevelSwitch":0},"content":"那只毛票更惨，幸亏跑的早 SYN应该是10合一 有文件了 不幸中的万幸","text":"那只毛票更惨，幸亏跑的早 SYN应该是10合一 有文件了 不幸中的万幸","html":"那只毛票更惨，幸亏跑的早 SYN应该是10合一 有文件了 不幸中的万幸"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":120159357,"gmtCreate":1624316527679,"gmtModify":1624316527679,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>这股情绪过了就那样了，买<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>不好么，短期、长持都很好","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>这股情绪过了就那样了，买<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>不好么，短期、长持都很好","text":"$AMC院线(AMC)$这股情绪过了就那样了，买$ContextLogic Inc.(WISH)$不好么，短期、长持都很好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/120159357","isVote":1,"tweetType":1,"viewCount":3803,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":358880080,"gmtCreate":1616679658040,"gmtModify":1616679658040,"author":{"id":"3573714277045690","authorId":"3573714277045690","name":"原谅我开始放纵了","avatar":"https://static.tigerbbs.com/0a1f2468f4bcebd55b27558ca544dc32","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>挂了个14.5止损居然被洗出去了我去","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>挂了个14.5止损居然被洗出去了我去","text":"$老虎证券(TIGR)$挂了个14.5止损居然被洗出去了我去","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/358880080","isVote":1,"tweetType":1,"viewCount":2411,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575622534241771","authorId":"3575622534241771","name":"Suky978","avatar":"https://static.tigerbbs.com/97a5dac4d73b811365babf732150c759","crmLevel":2,"crmLevelSwitch":0},"content":"是喜还是悲","text":"是喜还是悲","html":"是喜还是悲"}],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}